JP2022550560A5 - - Google Patents

Info

Publication number
JP2022550560A5
JP2022550560A5 JP2022520197A JP2022520197A JP2022550560A5 JP 2022550560 A5 JP2022550560 A5 JP 2022550560A5 JP 2022520197 A JP2022520197 A JP 2022520197A JP 2022520197 A JP2022520197 A JP 2022520197A JP 2022550560 A5 JP2022550560 A5 JP 2022550560A5
Authority
JP
Japan
Prior art keywords
lpxa
bordetella pertussis
seq
protein
recombinant bordetella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520197A
Other languages
English (en)
Japanese (ja)
Other versions
JP7650871B2 (ja
JP2022550560A (ja
Filing date
Publication date
Priority claimed from EP19200878.7A external-priority patent/EP3799884A1/en
Application filed filed Critical
Publication of JP2022550560A publication Critical patent/JP2022550560A/ja
Publication of JP2022550560A5 publication Critical patent/JP2022550560A5/ja
Application granted granted Critical
Publication of JP7650871B2 publication Critical patent/JP7650871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520197A 2019-10-01 2020-09-30 免疫原性組成物 Active JP7650871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200878.7 2019-10-01
EP19200878.7A EP3799884A1 (en) 2019-10-01 2019-10-01 Immunogenic compositions
PCT/EP2020/077416 WO2021064050A1 (en) 2019-10-01 2020-09-30 Immunogenic compositions

Publications (3)

Publication Number Publication Date
JP2022550560A JP2022550560A (ja) 2022-12-02
JP2022550560A5 true JP2022550560A5 (https=) 2023-09-27
JP7650871B2 JP7650871B2 (ja) 2025-03-25

Family

ID=68136165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520197A Active JP7650871B2 (ja) 2019-10-01 2020-09-30 免疫原性組成物

Country Status (12)

Country Link
US (1) US20220339277A1 (https=)
EP (2) EP3799884A1 (https=)
JP (1) JP7650871B2 (https=)
KR (1) KR20220070279A (https=)
CN (1) CN114502193A (https=)
AU (1) AU2020358775B2 (https=)
BR (1) BR112022005345A2 (https=)
CA (1) CA3156017A1 (https=)
IL (1) IL291559A (https=)
MX (1) MX2022003871A (https=)
WO (1) WO2021064050A1 (https=)
ZA (1) ZA202203363B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250263447A1 (en) * 2020-09-04 2025-08-21 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5388E (fr) 1905-06-08 1906-03-27 Jean Eugene Gabillon Radiateur à grand pouvoir refroidissant pour automobiles
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
ES2301181T3 (es) * 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JPWO2003050782A1 (ja) 2001-12-12 2005-04-21 株式会社法学館 演習問題出題システム
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2820133B1 (en) 2012-02-28 2017-08-02 The Board of Regents of The University of Texas System Synthetic lipid biology for combinatorial engineering of endotoxin
PL404247A1 (pl) * 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
KR102549847B1 (ko) 2016-07-28 2023-06-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 헤모필루스 인플루엔자 타입 b에 대항하는 백신으로서 안정한 가수분해-내성 합성 폴리리보실리비톨포스페이트 유도체
ES2992907T3 (en) * 2017-03-13 2024-12-19 Intravacc B V Bordetella vaccines comprising lps with reduced reactogenicity
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법

Similar Documents

Publication Publication Date Title
EP1970449B1 (en) Attenuated salmonella SPI2 mutants as antigen carriers
JP4827196B2 (ja) 髄膜炎菌類タンパク質nmb1870のドメインおよびエピトープ
JP3394774B2 (ja) コレラトキシンの免疫原性無毒化変異体およびトキシンltの免疫原性無毒化変異体,それらの調製,ならびにワクチンの調製のためのそれらの使用
CN104955835B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
EP2248535A1 (en) Multicomponent meningococcal vaccine
PT1076662E (pt) Proteínas transportadoras de poli-epítopos
JP2022550560A5 (https=)
JP2005508156A (ja) ナイセリアタンパク質のハイブリッドおよびタンデム発現
JP2001508286A (ja) 免疫原性の解毒変異体E.coli LT―A毒素
JP2019070035A (ja) 免疫原およびそのスクリーニング方法
US9884108B2 (en) Vaccine and therapeutic delivery system
JP2024156862A (ja) 百日咳ブースターワクチン
ES2370885T3 (es) Electroporación de mycobacterium y sobreexpresión de antígenos en micobacterias.
US6660261B1 (en) Bordetella strain expressing the FHA hybrid, liposomes and vaccines
Fooladi et al. Cellular immunity survey against urinary tract infection using pVAX/fimH cassette with mammalian and wild type codon usage as a DNA vaccine
Garrido et al. Heterologous protective immunization elicited in mice by Pasteurella multocida fur ompH
WO2003102170A1 (fr) Souches de bordetella rendues deficientes par attenuation genetique
JP6401148B2 (ja) 抗原および抗原の組み合わせ
JP5547657B2 (ja) パスツレラ・ムルトシダ(P.multocida)のfur細胞およびその外膜タンパク質の抽出物によるパスツレラ・ムルトシダ(Pasteurellamultocida)に対する異種性の防御
US20250263447A1 (en) Ompa mutations enhance omv production in bordetella pertussis
OA12130A (en) Attenuated microorganisms for the treatment of infection.
CN1748796A (zh) 结核转基因疫苗及其制备方法
JPH05503628A (ja) 新規なワクチン
AU2009273128A1 (en) Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis
CA2475993C (en) Defective entities and uses therefor